Loading viewer...
investor_presentation
Format: PDF investor_presentation
Kinnate Biopharma is a clinical-stage precision oncology company developing targeted therapies for cancer. The company's pipeline includes exarafenib (KIN-2787) for BRAF/NRAS-mutant melanoma and KIN-3248 for FGFR-driven cancers, with a proprietary Discovery Engine designed for rapid drug development.
investor_presentation
41 Pages
investor_presentation
46 Pages
Pantheon Resources PLC
NESR National Energy Services Reunited 2020 Investor Presentation
investor_presentationinvestor_presentation
31 Pages
National Energy Services Reunited Corp.
Oportun Financial Investor Presentation — August 2024
investor_presentationinvestor_presentation
39 Pages
Oportun Financial Corporation
investor_presentation
KBC Group